Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation

Sean W. Fanning, Christopher G. Mayne, Venkatasubramanian Dharmarajan, Kathryn E. Carlson, Teresa A. Martin, Scott J. Novick, Weiyi Toy, Bradley Green, Srinivas Panchamukhi, Benita S. Katzenellenbogen, Emad Tajkhorshid, Patrick R. Griffin, Yang Shen, Sarat Chandarlapaty, John A. Katzenellenbogen, Geoffrey L. Greene

Research output: Contribution to journalArticle

Abstract

Somatic mutations in the estrogen receptor alpha (ERα) gene (ESR1), especially Y537S and D538G, have been linked to acquired resistance to endocrine therapies. Cell-based studies demonstrated that these mutants confer ERα constitutive activity and antiestrogen resistance and suggest that ligand-binding domain dysfunction leads to endocrine therapy resistance. Here, we integrate biophysical and structural biology data to reveal how these mutations lead to a constitutively active and antiestrogen-resistant ERα. We show that these mutant ERs recruit coactivator in the absence of hormone while their affinities for estrogen agonist (estradiol) and antagonist (4-hydroxytamoxifen) are reduced. Further, they confer antiestrogen resistance by altering the conformational dynamics of the loop connecting Helix 11 and Helix 12 in the ligand-binding domain of ERα, which leads to a stabilized agonist state and an altered antagonist state that resists inhibition.

Original languageEnglish (US)
Article numbere12792
JournaleLife
Volume5
Issue numberFEBRUARY2016
DOIs
StatePublished - Feb 2 2016

Fingerprint

Estrogen Receptor alpha
Estrogen Receptor Modulators
Conformations
Breast Neoplasms
Mutation
Ligands
Estrogen Antagonists
Estrogens
Genes
Hormones
Therapeutics

ASJC Scopus subject areas

  • Neuroscience(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation. / Fanning, Sean W.; Mayne, Christopher G.; Dharmarajan, Venkatasubramanian; Carlson, Kathryn E.; Martin, Teresa A.; Novick, Scott J.; Toy, Weiyi; Green, Bradley; Panchamukhi, Srinivas; Katzenellenbogen, Benita S.; Tajkhorshid, Emad; Griffin, Patrick R.; Shen, Yang; Chandarlapaty, Sarat; Katzenellenbogen, John A.; Greene, Geoffrey L.

In: eLife, Vol. 5, No. FEBRUARY2016, e12792, 02.02.2016.

Research output: Contribution to journalArticle

Fanning, SW, Mayne, CG, Dharmarajan, V, Carlson, KE, Martin, TA, Novick, SJ, Toy, W, Green, B, Panchamukhi, S, Katzenellenbogen, BS, Tajkhorshid, E, Griffin, PR, Shen, Y, Chandarlapaty, S, Katzenellenbogen, JA & Greene, GL 2016, 'Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation', eLife, vol. 5, no. FEBRUARY2016, e12792. https://doi.org/10.7554/eLife.12792
Fanning, Sean W. ; Mayne, Christopher G. ; Dharmarajan, Venkatasubramanian ; Carlson, Kathryn E. ; Martin, Teresa A. ; Novick, Scott J. ; Toy, Weiyi ; Green, Bradley ; Panchamukhi, Srinivas ; Katzenellenbogen, Benita S. ; Tajkhorshid, Emad ; Griffin, Patrick R. ; Shen, Yang ; Chandarlapaty, Sarat ; Katzenellenbogen, John A. ; Greene, Geoffrey L. / Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation. In: eLife. 2016 ; Vol. 5, No. FEBRUARY2016.
@article{d0a04054ffd34680a1b906362e1e7dec,
title = "Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation",
abstract = "Somatic mutations in the estrogen receptor alpha (ERα) gene (ESR1), especially Y537S and D538G, have been linked to acquired resistance to endocrine therapies. Cell-based studies demonstrated that these mutants confer ERα constitutive activity and antiestrogen resistance and suggest that ligand-binding domain dysfunction leads to endocrine therapy resistance. Here, we integrate biophysical and structural biology data to reveal how these mutations lead to a constitutively active and antiestrogen-resistant ERα. We show that these mutant ERs recruit coactivator in the absence of hormone while their affinities for estrogen agonist (estradiol) and antagonist (4-hydroxytamoxifen) are reduced. Further, they confer antiestrogen resistance by altering the conformational dynamics of the loop connecting Helix 11 and Helix 12 in the ligand-binding domain of ERα, which leads to a stabilized agonist state and an altered antagonist state that resists inhibition.",
author = "Fanning, {Sean W.} and Mayne, {Christopher G.} and Venkatasubramanian Dharmarajan and Carlson, {Kathryn E.} and Martin, {Teresa A.} and Novick, {Scott J.} and Weiyi Toy and Bradley Green and Srinivas Panchamukhi and Katzenellenbogen, {Benita S.} and Emad Tajkhorshid and Griffin, {Patrick R.} and Yang Shen and Sarat Chandarlapaty and Katzenellenbogen, {John A.} and Greene, {Geoffrey L.}",
year = "2016",
month = "2",
day = "2",
doi = "10.7554/eLife.12792",
language = "English (US)",
volume = "5",
journal = "eLife",
issn = "2050-084X",
publisher = "eLife Sciences Publications",
number = "FEBRUARY2016",

}

TY - JOUR

T1 - Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation

AU - Fanning, Sean W.

AU - Mayne, Christopher G.

AU - Dharmarajan, Venkatasubramanian

AU - Carlson, Kathryn E.

AU - Martin, Teresa A.

AU - Novick, Scott J.

AU - Toy, Weiyi

AU - Green, Bradley

AU - Panchamukhi, Srinivas

AU - Katzenellenbogen, Benita S.

AU - Tajkhorshid, Emad

AU - Griffin, Patrick R.

AU - Shen, Yang

AU - Chandarlapaty, Sarat

AU - Katzenellenbogen, John A.

AU - Greene, Geoffrey L.

PY - 2016/2/2

Y1 - 2016/2/2

N2 - Somatic mutations in the estrogen receptor alpha (ERα) gene (ESR1), especially Y537S and D538G, have been linked to acquired resistance to endocrine therapies. Cell-based studies demonstrated that these mutants confer ERα constitutive activity and antiestrogen resistance and suggest that ligand-binding domain dysfunction leads to endocrine therapy resistance. Here, we integrate biophysical and structural biology data to reveal how these mutations lead to a constitutively active and antiestrogen-resistant ERα. We show that these mutant ERs recruit coactivator in the absence of hormone while their affinities for estrogen agonist (estradiol) and antagonist (4-hydroxytamoxifen) are reduced. Further, they confer antiestrogen resistance by altering the conformational dynamics of the loop connecting Helix 11 and Helix 12 in the ligand-binding domain of ERα, which leads to a stabilized agonist state and an altered antagonist state that resists inhibition.

AB - Somatic mutations in the estrogen receptor alpha (ERα) gene (ESR1), especially Y537S and D538G, have been linked to acquired resistance to endocrine therapies. Cell-based studies demonstrated that these mutants confer ERα constitutive activity and antiestrogen resistance and suggest that ligand-binding domain dysfunction leads to endocrine therapy resistance. Here, we integrate biophysical and structural biology data to reveal how these mutations lead to a constitutively active and antiestrogen-resistant ERα. We show that these mutant ERs recruit coactivator in the absence of hormone while their affinities for estrogen agonist (estradiol) and antagonist (4-hydroxytamoxifen) are reduced. Further, they confer antiestrogen resistance by altering the conformational dynamics of the loop connecting Helix 11 and Helix 12 in the ligand-binding domain of ERα, which leads to a stabilized agonist state and an altered antagonist state that resists inhibition.

UR - http://www.scopus.com/inward/record.url?scp=84978720091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978720091&partnerID=8YFLogxK

U2 - 10.7554/eLife.12792

DO - 10.7554/eLife.12792

M3 - Article

C2 - 26836308

AN - SCOPUS:84978720091

VL - 5

JO - eLife

JF - eLife

SN - 2050-084X

IS - FEBRUARY2016

M1 - e12792

ER -